VKTX Analyst Ratings
Viking Therapeutics, Inc. (VKTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $3.68B, listed on NASDAQ, employing roughly 45 people, carrying a beta of 0.71 to the broader market. Viking Therapeutics, Inc. Led by Brian Lian, public since 2015-04-28.
Consensus: Mixed from 0 analysts.
Price Targets
- Average Target
- $98.67
- High
- $101.00
- Low
- $95.00
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 1, 2026 | BTIG | maintain | Buy | Buy |
| Apr 30, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 12, 2025 | Canaccord Genuity | maintain | Buy | Buy |
| Oct 24, 2025 | JP Morgan | maintain | Overweight | Overweight |
How to Read VKTX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked VKTX analyst ratings questions
- What is the VKTX consensus price target?
- As of the latest aggregator update, Viking Therapeutics, Inc. (VKTX) carries a consensus 12-month price target of $98.67. Target ranges run from a low of $95.00 to a high of $101.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on VKTX?
- Analyst rating consensus is not currently available for VKTX.
- What recent ratings actions has VKTX seen?
- The five most recent ratings actions on VKTX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect VKTX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.